<DOC>
	<DOCNO>NCT00138099</DOCNO>
	<brief_summary>The investigator ' primary research objective : - To determine safety dalteparin prophylaxis , 5,000 IU once-daily , Intensive Care Unit ( ICU ) patient base : - proportion patient trough anti-Xa &gt; 0.40 IU/mL dalteparin prophylaxis 3 + 1 day , 10 + 1 day , 17 + 1 day dalteparin prophylaxis ; - risk major bleed treatment period . The investigator ' secondary research objective : - To determine pharmacokinetic property dalteparin prophylaxis ICU patient severe renal insufficiency ; - To identify clinical laboratory factor predict excessive anticoagulant effect ( anti-Xa &gt; 0.10 IU/mL ) ; - To estimate relationship trough anti-Xa level bleed . The DIRECT Pilot Study : Before embark large trial low molecular weight heparin ( LMWH ) versus standard unfractionated heparin ( UFH ) , DIRECT Study need observe whether bioaccumulation LMWH occur ICU patient moderate severe renal insufficiency , address potential problem protocol implementation .</brief_summary>
	<brief_title>Dalteparin 's Influence Renally Compromised : Anti-Ten-A Study ( DIRECT )</brief_title>
	<detailed_description>Critically ill patient admit intensive care unit ( ICU ) high risk deep vein thrombosis ( DVT ) , estimate 20-40 % patient develop DVT without prophylaxis . Preventing DVT important DVT usually clinically silent patient , first manifestation may life-threatening pulmonary embolism . About 30 % ICU patient renal insufficiency , base calculated creatinine clearance ( CrCl ) , patient 4-fold high risk DVT normal renal function . The current anticoagulant regimen use prevent DVT patient , consist unfractionated heparin ( UFH ) , 5000 IU twice-daily , may inadequate . A recent prospective cohort study research group investigate risk DVT 261 ICU patient find 10 % patient develop proximal vein DVT admission ICU despite receive UFH , 5000 IU twice-daily . In patient group high risk DVT , low-molecular-weight heparin ( LMWHs ) replace UFH DVT prophylaxis superior efficacy . Despite superior efficacy safety many patient , concern use LMWHs patient renal insufficiency LMWHs clear kidney . LMWH use patient might result excessive anticoagulant effect , potential increase bleeding . Much concern safety LMWH patient renal insufficiency pertain therapeutic-dose LMWH use treat DVT . Prophylactic- ( low ) dose LMWH use prevent DVT ICU patient 25-33 % therapeutic-dose . Three source evidence suggest prophylactic-dose LMWH may safe patient renal insufficiency . First , current evidence support fact prophylactic-dose LMWH accumulates avoid patient . Second , prophylactic-dose LMWH appear safe hemodialysis patient . Third , preliminary work research group suggest dalteparin , 5000 IU once-daily , accumulate ICU patient renal insufficiency . Thus , 0 10 ICU patient CrCl &lt; 50 mL/min/1.73m2 receive dalteparin detectable trough anticoagulant effect ( anti-Xa &gt; 0.10 IU/mL ) . Further , relationship CrCl peak anti-Xa level assess , correlation ( r &lt; 0.2 ) . Finally , 2 patient severe renal insufficiency ( CrCl &lt; 30 mL/min/1.73m2 ) receive dalteparin , 5000 IU once-daily , 9 trough anti-Xa value &lt; 0.10 IU/mL . No study investigate safety low-dose LMWH ICU patient impair renal function ; study complete , randomize trial assess efficacy low-dose LMWH DVT prophylaxis among ICU patient feasible . As first step address problem , propose open-label pilot study assess safety dalteparin prophylaxis , 5000 IU once-daily , ICU patient severe renal insufficiency . The safety propose dalteparin prophylaxis regimen assess determine risk excessive anticoagulant effect risk major bleeding . Dalteparin prophylaxis consider safe 2 criterion satisfied end treatment period : - proportion patient trough anti-Xa level &gt; 0.40 IU/mL ~10 % le ( exclude 17 % 95 % confidence ) ; - risk major bleed ~4 % le ( exclude 10 % 95 % confidence ) . If show dalteparin prophylaxis safe ICU patient severe renal insufficiency , improve patient care 2 way : - dalteparin may reduce risk DVT ( although test future trial ) ; - dalteparin would reduce heparin induce thrombocytopenia ( HIT ) , infrequent serious complication UFH .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Adult patient age &gt; 18 year Admitted ICU expect ICU length stay &gt; 72 hour Severe renal insufficiency , define calculate CrCl &lt; 30 mL/min/1.73m2 ICU admission &gt; 2 week time screen ICU admission within 3 month cardiac surgery neurosurgery Active bleed high risk bleed complication Thrombocytopenia ( platelet count &lt; 75 x 10^9/L ) time screen Coagulopathy ( International Normalized Ratio [ INR ] activate partial thromboplastin time [ aPTT ] &gt; 2 time upper limit normal ) time screen Patient indwell epidural catheter epidural analgesia within last 12 hour Receipt &gt; 2 dos LMWH ( prophylactic therapeuticdose ) ICU Receiving require therapeuticdose anticoagulation ( eg. , deep vein thrombosis [ DVT ] ) time screen Receiving dialysis require anticoagulation ( eg. , PRISMA , slow continuous ultrafiltration [ SCUF ] ) time screen Weight &lt; 45 kg Woman pregnant lactate Bilateral low limb amputation Previous adverse reaction heparin LMWH ( eg. , allergy , heparininduced thrombocytopenia [ HIT ] ) Contraindication receive blood product Life expectancy &lt; 14 day receive palliative care Prior enrolment study enrolment concurrent relate clinical trial Patient surrogate decisionmaker provide consent participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Critically ill patient ( ICU )</keyword>
	<keyword>Deep Venous Thromboembolism prevention</keyword>
	<keyword>Renal Failure</keyword>
	<keyword>Critically ill</keyword>
</DOC>